Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. | Available online http content 6 4 R326 Research article Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy a prospective single-centre study Amber Y Goedkoop1 2 Maarten C Kraan1 Daisy I Picavet2 Menno A de Rie2 Marcel BM Teunissen2 Jan D Bos2 and Paul P Tak1 Open Access Division of Clinical Immunology and Rheumatology Department of Internal Medicine Academic Medical Center University of Amsterdam Amsterdam The Netherlands 2Department of Dermatology Academic Medical Center University of Amsterdam Amsterdam The Netherlands Corresponding author Paul PTak Received 8 Feb 2004 Revisions requested 9 Mar 2004 Revisions received 1 Apr 2004 Accepted 1 Apr 2004 Published 26 May 2004 Arthritis Res Ther 2004 6 R326-R334 DOI ar1182 2004 Goedkoop etal. licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Psoriasis and psoriatic arthritis are inflammatory diseases that respond well to anti-tumour necrosis factor-a therapy. To evaluate the effects of anti-tumour necrosis factor-a treatment on expression of adhesion molecules and angiogenesis in psoriatic lesional skin and synovial tissue we performed a prospective single-centre study with infliximab therapy combined with stable methotrexate therapy. Eleven patients with both active psoriasis and psoriatic arthritis received infusions of infliximab 3 mg kg at baseline and at weeks 2 6 14 and 22 in an open-label study. In addition patients continued to receive stable methotrexate therapy in dosages ranging from 5 to 20 mg week. Clinical assessments including Psoriasis Area and Severity Index PASI and Disease Activity Score DAS were performed at baseline and every 2 weeks afterward. In .
